Longeveron (NASDAQ:LGVN – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.
Insider & Institutional Ownership
10.0% of Longeveron shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 11.2% of Longeveron shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Longeveron and CorMedix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -1,844.49% | -202.41% | -140.67% |
| CorMedix | 45.25% | 49.12% | 26.85% |
Volatility and Risk
Valuation & Earnings
This table compares Longeveron and CorMedix”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.20 million | 13.00 | -$22.70 million | ($1.13) | -0.59 |
| CorMedix | $311.71 million | 1.90 | $163.05 million | $2.13 | 3.54 |
CorMedix has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Longeveron and CorMedix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 1 | 1 | 2 | 0 | 2.25 |
| CorMedix | 1 | 1 | 6 | 0 | 2.63 |
Longeveron currently has a consensus price target of $5.50, suggesting a potential upside of 720.28%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 98.68%. Given Longeveron’s higher possible upside, equities analysts clearly believe Longeveron is more favorable than CorMedix.
Summary
CorMedix beats Longeveron on 11 of the 14 factors compared between the two stocks.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
